Dipeptidyl peptidase-IV inhibitors, a risk factor for bullous pemphigoid. Retrospective multicenter case-control study in France and Switzerland.

Benzaquen, Michael; Borradori, Luca; Berbis, Philippe; Cazzaniga, Simone; Valero, René; Richard, Marie-Aleth; Feldmeyer, Laurence (2018). Dipeptidyl peptidase-IV inhibitors, a risk factor for bullous pemphigoid. Retrospective multicenter case-control study in France and Switzerland. Journal of the American Academy of Dermatology, 78(6), pp. 1090-1096. Elsevier 10.1016/j.jaad.2017.12.038

[img]
Preview
Text
1-s2.0-S0190962217328785-main.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (282kB) | Preview
[img] Text
1-s2.0-S0190962217328785-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (216kB) | Request a copy

BACKGROUND Case reports have suggested an association between dipeptidyl peptidase-IV inhibitors (DPP4i) and development of bullous pemphigoid (BP). OBJECTIVE To evaluate the association between DPP4i treatment and development of BP. METHODS We conducted a retrospective 1:2 case-control study, comparing diabetic BP cases to age and sex-matched diabetic controls, issued from Swiss (Bern) and French (Marseille) dermatological departments, from January 1st 2014 to July 31st 2016. RESULTS We collected 61 diabetic BP patients and 122 controls. DPP4i were associated with an increased risk of developing BP (adjusted OR=2.64; 95% CI: 1.19-5.85; p=0.02), with vildagliptin showing the highest adjusted OR (3.57; 95% CI: 1.07-11.84; p=0.04). Stratified analysis showed a stronger association in males and patients aged 80 years or older. DPP4i withdrawal and the institution of first-line treatments led to clinical remission in 95% of cases. LIMITATIONS This was a retrospective study in tertiary referral hospitals. We focused the analysis on DPP4i intake, without analyzing the potential isolated effect of metformin. CONCLUSIONS DPP4i, especially vildagliptin, are associated with an increased risk of developing BP. Their use needs to be carefully evaluated, particularly in high-risk patients, such as males and those aged 80 years or older.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Borradori, Luca; Cazzaniga, Simone and Feldmeyer, Laurence

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0190-9622

Publisher:

Elsevier

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

29 Jan 2018 10:30

Last Modified:

22 Dec 2018 02:30

Publisher DOI:

10.1016/j.jaad.2017.12.038

PubMed ID:

29274348

Uncontrolled Keywords:

Dipeptidyl peptidase-IV inhibitor bullous pemphigoid case-control study diabetes gliptin risk factor

BORIS DOI:

10.7892/boris.110139

URI:

https://boris.unibe.ch/id/eprint/110139

Actions (login required)

Edit item Edit item
Provide Feedback